PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
|
|
- Opal Pamela Carr
- 6 years ago
- Views:
Transcription
1 PHARMACOLOGICAL TREATMENT OF ARTERIAL RESTENOSIS
2 PACLITAXEL VS RAPAMYCIN Paclitaxel essentially freezes the microtubules that are in place during cell division. The cells cannot complete cell division and recognizes that something is wrong and destroys itself. This process is called apoptosis or programmed cell death. Rapamycin works a little differently in that it affects a different pathway that essentially puts the cell to sleep and by doing that it prevents the cell from proliferating. Eventually the Rapamycin is metabolized and the cell wakes up and can operate normally again.
3 PACLITAXEL PREVENTS CELLULAR DIVISION AND REPLICATION, Drug PROVIDING A STRONG ANTI-RESTENOTIC EFFECT Paclitaxel (Cytotoxic) Interferes with cell division Rapamycin/Sirolimus (Cytostatic) Interferes with cell growth Cytotoxic drugs stabilize microtubules, preventing division in the final stages of the cellular replication cycle and leading to cell death (apoptosis) M G 2 Mitosis Cell prepares for mitosis G 1 Protein synthesis DNA synthesis S Cytostatic drugs hold a cell in G 0 phase, arresting growth but allowing cell to continue functioning 3 3 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
4 STUDIES SHOWING CHANGES IN NEOINTIMAL INHIBITION BASED ON VARYING CONCENTRATIONS OF PACLITAXEL Drug Dose-dependent response up to 3-4 µg/mm 2 (effective dose) Less than a ~2.5 μg/mm 2 dose shows a decreased therapeutic benefit Above a 4 μg/mm 2 dose indicates a limited, incremental efficacy gained 1. Margolis J, McDonald J, Heuser R, Klinke P,Waksman R,VirmaniR Desai N, Hilton D. Systemic nanoparticle paclitaxel (nab-paclitaxel) for in-stent restenosis I (SNAPIST-I): A first-in-human safety and dose-finding study. Clin Cardiol 2007;30: Cremers B et al. Comparison of two di erent paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2009; 98: Cremers B. et al Drug-eluting balloon: Very short-term exposure and overlapping. Thromb Haemost 2009; 101: Scheller B. et al. Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis Circulation. 2004;110: Speck U, Scheller B, Abramjuk C, et al. Neointima inhibition: comparison of effectiveness of nonstent-based local drug delivery and a drug-eluting stent in porcine coronary arteries. Radiology. 2006;240: Rowinsky EK, Donehower RC. Paclitaxel (Taxol).N engl J Med 1995;332: UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
5 PACLITAXEL CONCENTRATIONS FOLLOWING TREATMENT SUGGEST BOTH SAFETY AND EFFICACY Drug Tissue Detectable levels of drug over 180 days in both arms (therapeutic dose and 3x safety margin) At 320 days no quantifiable drug is identified in the targeted tissue area (therapeutic dose) Plasma No drug quantified after 48 hours (therapeutic dose) No drug quantified after 672 hours (3x safety margin dose ) Drug concentrations drop 50% within the first 30 min Safety Margin=3x dose Porcine ilio-femoral model - Data on file at Medtronic Inc. 5 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
6 AN EXCIPIENT SUPPORTS THE UPTAKE OF DRUG BY VESSEL TISSUE Acts as a molecular spacer to increase paclitaxel surface exposure Facilitates paclitaxel transfer through its hydrophilic properties Excipient Tissue Concentration Blood Concentration R.Virmani CIRSE 2012 Oral Presentation 6 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
7 COATING TECHNOLOGY PROVIDES RELIABLE AND UNIFORM DRUG DELIVERY Coating DESIGN OBJECTIVE: DURABLE / SCALABLE COATING Balloon coating in semi-inflated shape: DESIGN OBJECTIVE: UNIFORM COATING Longitudinal Coating Thickness Circumferential Coating ~ 60-70% of dose protected within balloon folds 1 1 experimental data on file at Medtronic 7 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
8 Mechanism of Action DCB MECHANISM OF ACTION FACILITATES THE TRANSFER OF DRUG DEEP INTO VESSEL TISSUE IN.PACT Admiral balloon matrix coating: Paclitaxel Urea - excipient that controls drug release DCB inflation: Matrix coating contact with the blood Urea hydrates causing the release of paclitaxel Paclitaxel binds to the wall due to its hydrophobic and lipophilic properties Paclitaxel penetration: Through vessel wall deep into the media and adventitia Interferes with the causes of restenosis Can remain in the vessel wall for over 180 days at therapeutic levels 1 1 Data on file at Medtronic (GLP Study FS208; GLP Study PS516) 8 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
9 Treatment Strategy PROVISIONAL STENTING RATE IS DEPENDENT ON LESION LENGTH Scaffolds still needed but likely at rates proportional to lesion complexity Provisional stent rates in DCB trials are a function of lesion length [1] Rosenfield K TCT 2013; [2] Tepe G et al. N Engl J Med 2008; [3] Tepe CX 2014; [4] Werk M et al. Circulation 2008; [5] Micari A et al. J Am Coll Cardiol Intv 2012; [6] Zeller T CX 2013 oral presentation; [7] Werk et al. Circ Cardiovasc Interv. 2012; [8] Schmidt A LINC 2013 oral presentation 9 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
10 Primary Patency Late Lumen Loss DEB IS EFFECTIVE IN CALCIFIED Objective: Assess effect of calcium on IN.PACT DCB efficacy 60-patient registry SFA de-novo: average Lesion Length 6.1 cm Chronic Total Occlusion: 31.7% Systematic PTA pre-dilatation followed by IN.PACT DCB Treatment Strategy LESIONS Calcium distribution and severity affect Late Lumen Loss and Primary Patency Severe calcium may represent a barrier to drug absorption F.Fanelli LINC 2013 Calcium Evaluation Calcium distribution evaluation by CTA (circumferential) and DSA (longitudinal) 10 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
11 IN.PACT SFA Trial IN.PACT ADMIRAL IS THE NEW STANDARD FOR PRIMARY PATENCY Highest Reported Primary Patency of all SFA Technologies* (p<0.001 by log-rank test) Primary patency is defined as freedom from clinically-driven TLR and freedom from restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) 2.4 *Qualitative Comparison. Not Meant for Head-to-Head Comparison. 11 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
12 DEB: THE NEW STANDARD FOR CD-TLR Lowest Reported Clinically-Driven TLR rate of all SFA Technologies* IN.PACT SFA Trial Clinically-Driven Target Lesion Revascularization (TLR) at 12 Months 25% 20% P< % 15% 10% 5% 2.4% 0% IN.PACT Admiral PTA 1. Clinically-driven TLR defined as any re-intervention due to symptoms or drop of ABI/TBI of >20% or >0.15 compared to post-procedure ABI/TBI 2. Actual event rate by frequency ratio algorithm calculation *Qualitative Comparison. Not Meant for Head-to-Head Comparison. 12 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
13 Treatment Strategy TREATMENT STRATEGY AVOID GEOGRAPHIC MISS Pre-dilatation Drug-Coated Balloon (Primary Therapy) Spot Stent Postdilatation STAY WITHIN DCB AREA 1. PRE-DILATATION Required for all lesions, prior to DCB procedure Standard PTA 1 mm less than reference vessel diameter (RVD) Balloon length should not be greater than the planned DCB length 2. ATHERECTOMY Recommended in severely calcified lesions 3. DRUG-COATED BALLOON DCB diameter:rvd = 1:1; length 1 cm beyond lesion on both ends Inflation time 3 minutes Inflation pressure < RBP as required to reach full DCB expansion 4. POST-DILATATION If residual stenosis 50% or flow limiting dissection Standard or high pressure PTA balloon diameter 1:1 to RVD Short / focal length as necessary to treat the extent of residual stenosis or dissection 5. PROVISIONAL SPOT STENTING For persistent residual stenosis 50% or flow limiting dissections Minimum length as necessary to fully treat the residual stenosis or dissection 13 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
14 Perivascular tissue Adventitia Media Lumen 14 RESTENOSIS SUMMARY Lumen loss INJURY Stretching Denudation Leukocyte adherence Negative remodeling Neointima Recoil Injury response programs Inflammation Phenotypic switch: quiescent proliferative and synthetic Recruitment Proliferation Fibrosis Inflammation Progenitor cell differentiation Myofibroblast proliferation Fibrosis Microvascular networks Paracrine factors Lumen loss
15 15 RESTENOSIS BEGINS WITH INFLAMMATION INJURY INFLAMMATION, RECRUITMENT PROLIFERATION, MIGRATION FIBROSIS, HYPERPLASIA Timeframe: Hours to Days Weeks Months Agents: Dexamethasone Paclitaxel, -limus compounds
16 16 INFLAMMATION IS AT THE ROOT OF RESTENOSIS
17 17 DANCE STUDY DESIGN clinical effectiveness evaluation of adventitial DEX after PAD intervention, vs contemporary published data Prospective, Single Arm, Multicenter Trial Subject population (n=300), 150 ATX / 150 PTA Assess safety and feasibility of perivascular dexamethasone delivery following SFA/popliteal artery revascularization OBJECTIVE: To evaluate effectiveness outcomes of adventitial DEX delivered by Bullfrog Device SFA / Pop Lesion Successful crossing of lesion & successful revasc. Dex Delivery Bullfrog Micro- Infusion Catheter injection Followup 1, 6, 12, 18, 24
18 18 DANCE N=300 De novo or non-stented restenotic SFA and/or popliteal lesions > 70% Lesions maximum 15 cm in length Rutherford 2-4 Enrollment complete 12/15/2015 Baseline angiogram and biomarker blood draw (1/3 of pts) Enrolled Subjects to be followed for 24 Months 150 PTA 150 atherectomy Adventitial DEX treatment 24-hour blood draw for biomarkers (1/3 of pts) 1-month blood draw for biomarkers (1/3 of pts) Clinical, hemodynamic and duplex U/S follow-up at 1, 6, 12, 18, 24 months
19 19 THE BULLFROG MICRO-INFUSION DEVICE
20 20 EXAMPLE BULLFROG CASE Angioplasty used to open vessel.... Bullfrog device inserted to distal target first After drug delivery to paint the vessel, follow up angiogram shows good result
21 SUCCESSFUL INFUSION 21 Bullfrog Device with balloon inflated After 3 minutes, Full perivascular dispersion >15cm of SFA Inflated Bullfrog Micro- Infusion Device
22 22 WHAT S NEXT BTK Study US Kicking off Q BTK Study Germany/OUS Kicking off January 2016
23 Treatment Strategy TREATMENT STRATEGY AVOID GEOGRAPHIC MISS Pre-dilatation Drug-Coated Balloon/infusion (Primary Therapy) Postdilatation 1. PRE-DILATATION Required for all lesions, prior to DCB procedure Standard PTA 1 mm less than reference vessel diameter (RVD) Balloon length should not be greater than the planned DCB length 2. ATHERECTOMY Recommended in severely calcified lesions 3. DRUG-COATED BALLOON vs DIRECT MEDIAL INFUSION 4. PROVISIONAL SPOT STENTING For persistent residual stenosis 50% or flow limiting dissections Minimum length as necessary to fully treat the residual stenosis or dissection Spot Stent STAY WITHIN DCB AREA 23 UC EN Medtronic, Inc All Rights Reserved. Medtronic Confidential. For distribution in the US only. 12/14
Disclosures. How many people have heard a talk on DCBs? By show of hands, how many people here have used a DCB?
Disclosures Drug Coated Balloons: How they work and what s the evidence? Christopher D. Owens, MD, MSc UCSF vascular surgery I am paid to talk about peripheral interventional procedures by Medtronic and
More informationDrug- Coated Balloons for the SFA: Overview of Technology and Results
Drug- Coated Balloons for the SFA: Overview of Technology and Results NCVH Latin American 2015 Bogota, Colombia April 9-11, 2015 Brian G. DeRubertis, M.D. Associate Professor of Surgery Division of Vascular
More informationAdventitial Drug Infusion to Prevent Restenosis
Adventitial Drug Infusion to Prevent Restenosis Marianne Brodmann, M.D. University of Graz Graz, Austria Disclosure Speaker name: Marianne Brodmann... I have the following potential conflicts of interest
More informationTHE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES
THE SCIENCE BEHIND DRUG COATED BALLOONS OUTCOMES THE IDEA AND THE TECHNOLOGY FRANCESCO JATTA, PH.D. PROGRAM MANAGER DISCLOSURES I have the following potential conflicts of interest to report: Consulting
More informationDrug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationFinal Results of the Feasibility Study for the Drug-coated Chocolate Touch PTA balloon. (The ENDURE Trial)
Final results of the feasibility study for the drug-coated Chocolate Touch PTA balloon of of femoropopliteal Femoropopliteal lesions lesions: (The ENDURE Trial) Final Results of the Feasibility Study for
More informationOutcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry
Outcomes Of DCB Use In Real World Registries: 2 Year Results From The INPACT Global Registry Marianne Brodmann, MD Head of the Clinical Division of Angiology Department of Internal Medicine Medical University
More informationAlternative concepts for drug delivery in BTK arteries the LIMBO project
Alternative concepts for drug delivery in BTK arteries the LIMBO project Dierk Scheinert, MD Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Speaker s name: Dierk
More informationClinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD
Clinical Data Update for Drug Coated Balloons (DCB) Seung-Whan Lee, MD, PhD Asan Medical Center, Heart Institute, University of Ulsan College of Medicine, Werk et al. Circulation Cardiovasc Intervent 2012
More information12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort. Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany
12-month Outcomes of Post Dilatation in the IN.PACT Global CTO Cohort Gunnar Tepe, MD RodMed Clinic Rosenheim Rosenheim, Germany Disclosure Speaker name: Gunnar Tepe I have the following potential conflicts
More informationDrug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND
Drug eluting stents and balloons in peripheral arterial disease A.T.O. ABDOOL-CARRIM UNIVERSITY OF WITWATERSRAND Drug eluting stents and balloons Endovascular treatment now becoming more popular for treatment
More informationMICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES. Medtronic Further. Together
DRUG-COATED BALL0ON TREATMENT FOR PATIENTS WITH INTERMITTENT CLAUDICATION: INSIGHTS FROM THE IN.PACT GLOBAL FULL CLINICAL COHORT MICHAEL R. JAFF, DO MASSACHUSETTS, UNITED STATES Medtronic Further. Together
More informationILLUMENATE FIH Direct DCB Cohort 12-Month Results
ILLUMENATE FIH Direct DCB Cohort 12-Month Results Stephan Duda Berlin Study Investigators: H. Schröder (PI), B. Lux, F. Rücker, M. Martorana, D. Meyer, H. Hartmann, S. Duda Disclosure Speaker name: S.
More informationLong Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA
Long Lesions: Primary stenting or DCB first? John Laird MD Adventist Heart and Vascular Institute, St. Helena, CA Disclosures John R. Laird Within the past 12 months, I or my spouse/partner have had a
More informationEfficacy of DEB in Calcification and Subintimal Angioplasty
Efficacy of DEB in Calcification and Subintimal Angioplasty Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC Div of Cardiovascular Intervention and Research Cardiovascular Center, Korea University
More informationDrug-coated balloons in BTK:
Drug-coated balloons in BTK: Where do we stand and what are the open questions? Dr. Marc Bosiers LINC 2019 - Leipzig My disclosures x o I do not have any potential conflicts of interest to report o I have
More informationThe TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy
The TANGO Trial: A phase II below-the-knee study investigating the adventitial micro-infusion of Temsirolimus after PTA or atherectomy Ian Cawich, MD Arkansas Heart Hospital Little Rock, Arkansas, USA
More informationPromise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
More informationRANGER SFA REGISTRY Interim Analysis. Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators
RANGER SFA REGISTRY Interim Analysis Bernd Gehringhoff, MD On behalf the Ranger SFA Registry Investigators Conflict of Interest - Disclosure Within the past 12 months, I or my spouse/partner have had a
More informationBIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort
BIOLUX P-III Passeo-18 Lux All-comers Registry: 12-month Results for the All-Comers Cohort Prof. Dr. Gunnar TEPE, Klinikum Rosenheim, Germany CCI on behalf of the BIOLUX P-III Investigators Disclosure
More informationVessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA
Vessel Preparation: What does it mean and what are the current tools? Lawrence Garcia, MD St. Elizabeth s Medical Center Boston, MA, USA Disclosure Statement of Financial Interest Within the past 12 months,
More informationMichael K.W. Lichtenberg, MD
Ranger All-Comer Registry Treatment of femoropopliteal atherosclerotic lesions using the Drug eluting Balloon Ranger: An All Comers Registry Michael K.W. Lichtenberg, MD Klinikum Arnsberg Arnsberg, Germany
More informationRationale and algorithm for below-the-knee acute gain optimization
Leipzig, 01 Feb. 2018 Rationale and algorithm for below-the-knee acute gain optimization Flavio Airoldi, MD Flavio Airoldi Multimedica IRCCS Milan ITALY flavio.airoldi@multimedica.it Rationale Restenosis
More informationNew approaches for drug delivery in BTK arteries
New approaches for drug delivery in BTK arteries Dierk Scheinert, MD Department of Angiology University of Leipzig, Germany Disclosure Dierk Scheinert, MD Advisory Board /Consultant: Abbott, Bayer, Boston
More informationManagement of In-stent Restenosis after Lower Extremity Endovascular Procedures
Management of In-stent Restenosis after Lower Extremity Endovascular Procedures Piotr Sobieszczyk, MD Associate Director, Cardiac Catheterization Laboratory Cardiovascular Division and Vascular Medicine
More informationThe Role of Lithotripsy in Solving the Challenges of Vascular Calcium. Thomas Zeller, MD
The Role of Lithotripsy in Solving the Challenges of Vascular Calcium Thomas Zeller, MD 1 1 Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: X X
More informationEvolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data
Evolving Role of Drug-Eluting Stents In Complex SFA - Majestic Trial Data Ralf Langhoff, MD Center for Vascular Medicine Berlin-Wilmersdorf St. Gertrauden Hospital Charité, CC11 Academic Teaching Hospitals
More informationThe drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY
The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY Safety and efficacy of the Drug Eluting Balloon (DEB) for the treatment of the Superficial Femoral Artery (SFA) ischemic
More informationAdventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO
Adventitial Drug Therapy Below-the-Knee: Update on LIMBO and TANGO Ehrin J. Armstrong, MD, FACC University of Colorado School of Medicine VA Eastern Colorado Healthcare System Denver, Colorado, USA Disclosure
More informationEndovascular Innovations Today and Tomorrow. Zaheed Tai, DO, FACC, FSCAI Winter Haven Hospital Heart of Florida
Endovascular Innovations Today and Tomorrow Zaheed Tai, DO, FACC, FSCAI Winter Haven Hospital Heart of Florida Prevalence (Millions) Prevalence of PAD in the US 16 14 PAD currently affects 8 12 million
More informationTOBA II 12-Month Results Tack Optimized Balloon Angioplasty
TOBA II 12-Month Results Tack Optimized Balloon Angioplasty William Gray, MD System Chief, Cardiovascular Division Main Line Health, Philadelphia, PA Dissection: The Primary Mechanism of Angioplasty Lesions
More informationThe drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY
The drug-eluting balloon superficial femoral artery-long study THE DEB SFA-LONG STUDY Safety and efficacy of the Drug Eluting Balloon (DEB) for the treatment of the Superficial Femoral Artery (SFA) ischemic
More informationUpdate on the role of drug eluting balloons
Update on the role of drug eluting balloons William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular Research
More informationIs combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease?
Is combination therapy with directional atherectomy followed by DCB the answer to challenges in treating SFA disease? The REALITY trial G. Torsello Münster Disclosure Speaker name: G. Torsello... I have
More information4/14/2016. Faculty Disclosure. Drug-eluting technology in the SFA and Popliteal. Typical SFA Disease Pattern. Why Peripheral Artery Disease Matters
Drug-eluting technology in the SFA and Popliteal David Paul Slovut, MD, PhD Associate Professor of Medicine and Surgery Co-director of TAVR program Director of Advanced Intervention Faculty Disclosure
More informationOne Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
More informationDURABLE. CONSISTENT. SAFE. IN.PACT Admiral Drug-Coated Balloon
DURABLE. CONSISTENT. SAFE. Drug-Coated Balloon THE SCIENCE BEHIND THE OUTCOMES DCB has proven, long-term durable outcomes across multiple clinical trials, as well as across complex patient and lesion types.
More informationLessons learnt from DES in the SFA is there any ideal concept so far?
Wednesday, January 25, 2017 - Time: 11:49-11:55 DEEP DIVE SESSION: Lower limb interventions (part II) Lessons learnt from DES in the SFA is there any ideal concept so far? S.Müller-Hülsbeck, MD, EBIR,
More informationImportance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study
Importance of Thorough Vessel Preparation Followed By Anti- Restenotic Therapy: An Update from the DEFINITIVE AR Study Gunnar Tepe, MD Romed Klinikum, Rosenheim, Germany On behalf of the DEFINITIVE AR
More informationThe latest generation DEB
The latest generation DEB V. Riambau, MD. PhD Prof. and Chief of Vascular Surgery Division, Cardiovascular Institute, Hospital Clínic of Barcelona University of Barcelona Consultant: Bolton Medical/ Medtronic/
More informationCould a combination of DCB + stent be the answer in complex SFA lesions
Could a combination of DCB + stent be the answer in complex SFA lesions Sven Bräunlich, MD Division of Interventional Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich
More informationFuture Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit?
Future Algorithm for Lower Extremity Revascularization: Where Does Vessel Prep Fit? John R. Laird Adventist Heart and Vascular Institute St. Helena, CA Disclosure Speaker name: John R. Laird... I have
More informationDCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
More informationClinical benefits on DES Patient s perspectives
Clinical benefits on DES Patient s perspectives Dr. Skyi Pang Vascular Surgeon Department of Surgery Pamela Youde Nethersole Eastern Hospital Hong Kong Disclosure Speaker name: Skyi Pang... I have the
More informationThe LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint
The LIMBO trial: a RCT investigating adventitial dexamethasone infusion to prevent restenosis in BTK arteries utilizing a novel angiographic endpoint Dr. Ulrich Beschorner Universitäts Herzzentrum Freiburg
More informationKlinikum Rosenheim Department of Diagnostic and Interventional Radiology
Klinikum Rosenheim Department of Diagnostic and Interventional Radiology Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results
More informationCLI: Patient level Risk Factors and CLI Outcomes
Disclosures CLI: Patient level Risk Factors and CLI Outcomes CHRISTOPHER D. OWENS MD, MSC UCSF VASCULAR SURGERY I am paid to talk about peripheral interventions by BARD and Medtronic CLI Natural Evolution:
More informationBTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration
BTK Intervention with Drug- Coated Balloons: Past Lessons and Future Exploration M Sapoval, C Del Giudice, C Dean Interventional Radiology Dep Hôpital Européen Georges Pompidou APHP, Paris, France IMPORTANT
More informationThe importance of scientific evidence. Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern
The importance of scientific evidence Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner... I have the following potential
More informationAre Drug-coated balloons Durable? Level 1 evidence review. Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium
Are Drug-coated balloons Durable? Level 1 evidence review Koen Keirse, MD Vascular Surgery, RZ Tienen Tienen, Belgium Disclosure Speaker name: Koen Keirse, MD I have the following potential conflicts of
More informationIN ARTERIOVENOUS FISTULA FAILURE
DRUG ELUTING BALLOON ANGIOPLASTY IN ARTERIOVENOUS FISTULA FAILURE Nicola Troisi, MD GUIDELINES GUIDELINES VAS 2007 GUIDELINES VAS 2007 GUIDELINES VAS 2007 GUIDELINES VAS 2007 2007!!!!!!!!!! GUIDELINES
More informationNew Data to Shape the Era of Drug Elution in Peripheral Interventions
New Data to Shape the Era of Drug Elution in Peripheral Interventions William A. Gray MD Director of Endovascular Services Columbia University Medical Center New York Lower Extremity Endovascular - Interventions
More informationMaking BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD
Making BTK Interventions more Durable: Are DES and DCB the answer? Thomas Zeller, MD Faculty Disclosure Thomas Zeller, MD For the 12 months preceding this presentation, I disclose the following types of
More informationUpdate from Korea on the Lutonix SFA registry 12 month data
Update from Korea on the Lutonix SFA registry 12 month data Prospective, Multicenter, Post-Market Registy Assessing the Clinical Use and Safety of the Lutonix Drug Coated Balloon in Femoropopliteal Arteries
More informationLatest Insights from the LEVANT II study and sub-group analysis
Latest Insights from the LEVANT II study and sub-group analysis Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University-Hospital Leipzig, Germany Conflicts of Interest Advisory Board
More informationAdventitial Drug Therapy for Critical Limb Ischemia
Adventitial Drug Therapy for Critical Limb Ischemia Ehrin J. Armstrong, MD, FACC University of Colorado School of Medicine VA Eastern Colorado Healthcare System Denver, Colorado, USA Disclosure Speaker
More informationContemporary use of DCBs, Ranger clinical trial and investigator sponsored research
Contemporary use of DCBs, Ranger clinical trial and investigator sponsored research Dierk Scheinert, MD Division of Interventional Angiology University-Hospital, Leipzig, Germany IMPORTANT INFORMATION:
More informationNovel concept for drug delivery in infrapopliteal arteries The LIMBO trial
Novel concept for drug delivery in infrapopliteal arteries The LIMBO trial Prof. Dr. med. Dierk Scheinert Division of Interventional Angiology University Hospital Leipzig, Germany 1 Disclosure Advisory
More informationDierk Scheinert, MD. Department of Angiology University Hospital Leipzig, Germany
The RANGER clinical trial programme: 12-month results from the RANGER RCT and first look at the COMARE I study of RANGER vs. IN.PACT for femoropopliteal lesions Dierk Scheinert, MD Department of Angiology
More informationPatterns of Vessel Calcification and Clinical Relevance
Patterns of Vessel Calcification and Clinical Relevance Michael R. Jaff, DO Paul and Phyllis Fireman Endowed Chair in Vascular Medicine Massachusetts General Hospital Professor of Medicine Harvard Medical
More informationAtherectomy is Still Live and Effective. John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System
Atherectomy is Still Live and Effective John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center UC Davis Health System Why is Atherectomy Still Alive? Improved devices Better data
More informationESVB State of the art: DES, DCB and the role of debulking. Gunnar Tepe, Rosenheim
ESVB 2013 State of the art: DES, DCB and the role of debulking Gunnar Tepe, Rosenheim DES I Sirocco Sirolimus coating, quick release Duda et al., J Vasc Surg 2002; 106: 1505-1509 20 DES II Strides Everolimus
More informationThe Evolution of SFA Treatment Strategy with IN.PACT DCB
The Evolution of SFA Treatment Strategy with IN.PACT DCB JOS VAN DEN BERG, MD OSPEDALE REGIONALE DI LUGANO LUGANO, SWITZERLAND RAPHAEL COSCAS, MD HÔPITAL AMBROISE PARÉ BOULOGNE BILLANCOURT, FRANCE ROBERTO
More informationChristian Wissgott MD, PhD Assistant Director, Radiology Westküstenkliniken Heide
2-Year Results Of The Tack Optimized Balloon Angioplasty (TOBA) Trial For Fem- Pop Lesions Demonstrates Safety and Efficacy Of The Tack Endovascular System In Repairing Focal Post-PTA Dissections Christian
More informationMaximizing Outcomes in a complex population with Drug-coated balloon
Maximizing Outcomes in a complex population with Drug-coated balloon March 13, 2018 Chumpol Wongwanit, MD Siriraj Hospital, Mahidol University, Bangkok, Thailand LINC Asia-Pacific 2018, Hong Kong Disclosure
More informationMerits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁
Merits and demerits of DES, DEB or covered stent in lower extremity arterial occlusive disease 성균관의과대학삼성서울병원순환기내과최승혁 Contents DES in SFA DES in BTK DEB in SFA DEB in BTK Current status of covered stent
More information2 Year Results from the MDT SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA
2 Year Results from the MDT- 2113 SFA Japan Trial - DCB vs. standard PTA for the treatment of atherosclerotic lesions in the SFA/PPA Osamu Iida, MD - Kansai Rosai Hospital, Hyogo, Japan Hiroyoshi Yokoi,
More informationAlternative methods of drug delivery in BTK vessels Initial insights from the TANGO trial
Alternative methods of drug delivery in BTK vessels Initial insights from the TANGO trial Ehrin Armstrong, MD, FACC Colorado University School of Medicine VA Eastern Colorado Healthcare System Denver,
More informationUpdate on the OPTIMIZE BTK Trial. Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria
Update on the OPTIMIZE BTK Trial Marianne Brodmann, MD Division of Angiology Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann, MD... I have the following potential conflicts
More informationIs a Stent or Scaffold Necessary in The SFA?
1 2 3 Is a Stent or Scaffold Necessary in The SFA? Stents were developed to optimize acute results after angioplasty Specifically, stents are universally accepted to manage flow limiting dissections and
More informationCutting/scoring balloon Cryoplasty Drug-eluting balloon Brachytherapy Debulking Restent (BMS or DES) John R. Laird, MD
Current Treatment of Femoropopliteal Instent Restenosis Professor of Medicine Medical Director of the Vascular Center UC Davis Medical Center SFA In-stent Restenosis Common: 18%- 40% at 12 months in recent
More informationUpdate on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee. Marianne Brodmann, MD Medical University Graz Graz, Austria
Update on Tack Optimized Balloon Angioplasty (TOBA) Below the Knee Marianne Brodmann, MD Medical University Graz Graz, Austria Critical Limb Ischemia Infrapopliteal arterial disease is a leading source
More informationDo we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
More informationInnovations are created to solve the limitations of an
Sponsored by Lutonix, Inc. Defining the Next Generation of Drug-Coated Balloon Technology BY KEN ROSENFIELD, MD, AND STEPHAN DUDA, MD Innovations are created to solve the limitations of an existing technology
More informationHow DCB drug dose effects vessel healing. Aloke Finn, MD CVPath Institute Inc. Gaithersburg, MD. USA
How DCB drug dose effects vessel healing Aloke Finn, MD CVPath Institute Inc. Gaithersburg, MD. USA Disclosure Statement of Financial Interest Speaker's name : Aloke, Finn, Gaithersburg I have the following
More informationUpdate on the Ranger clinical trial programme
Update on the Ranger clinical trial programme Dierk Scheinert, MD Universitätsklinikum Leipzig, Leipzig, Germany on behalf of the RANGER SFA investigators Disclosure Speaker s name: Dierk Scheinert I have
More informationLegflow DCB Safety / outcomes from the clinical trial program
Legflow DCB Safety / outcomes from the clinical trial program Peter Goverde MD, Loes Helsloot MD, Kim Taeymans MD, Jan Bontink MD, Katrien Lauwers MD, Paul Verbruggen MD Vascular Clinic ZNA, Antwerp, Belgium
More informationRole of Covered Stents and Drug Eluting Balloons In Dialysis Access
Role of Covered Stents and Drug Eluting Balloons In Dialysis Access Joseph Habib, MD, FACS Assistant Professor Department of Surgery Division of Vascular and Endovascular Surgery University of Florida
More informationCOMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions. Dierk Scheinert
COMPARE-Pilot RCT: 1-year results of a randomised comparison of RANGER DCB vs. IN.PACT DCB in complex SFA lesions Dierk Scheinert Department of Angiology University Hospital Leipzig, Germany Disclosure
More informationDealing with Calcification in BTK Arteries: Is Lithoplasty the Answer?
Dealing with Calcification in BTK Arteries: Is Lithoplasty the Answer? Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC 2017 January 25 th 2017 Disclosure
More information6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen
First Report of the SELUTION Trial: 6-month 0utcomes of a Novel Sirolimus Coated DCB Technology Evaluated in SFA Thomas Zeller, MD University Heart Center Freiburg-Bad Krozingen On behalf of the SELUTION
More informationDrug delivery devices for BTK treatment
LINC AP 2016, Hong Kong A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Drug delivery devices for BTK treatment Patrick Peeters Jürgen Verbist W. Van
More informationDCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
More informationREACT Treatment Rationale and Clinical Evidence. ICI Meeting 5th of December 2017
REACT Treatment Rationale and Clinical Evidence ICI Meeting 5th of December 2017 The SFA is a challenging vessel to treat Shortening 23-25%1 Compression > 1kg2 Torsion 60 3 Bending 64 4 SFA, superficial
More informationVessel Preparation Prior to DCB and Stenting: How to Do It.
Vessel Preparation Prior to DCB and Stenting: How to Do It. LINC 2018 January 30 February 2, 2018 Leipzig, Germany Brian DeRubertis, MD, FACS Associate Professor of Surgery UCLA Division of Vascular Surgery
More informationCurrent Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis
Current Status and Limitations in the Treatment of Femoropopliteal In-Stent Restenosis Osamu Iida, MD From the Kansai Rosai Hospital Cardiovascular Center, Amagasaki City, Japan. ABSTRACT: Approximately
More informationIN.PACT AV Access IDE Study Full Baseline Data. Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators
IN.PACT AV Access IDE Study Full Baseline Data Robert Lookstein, MD MHCDL New York, NY On Behalf of the IN.PACT AV ACCESS Investigators Disclosures Speaker name: Robert Lookstein, MD... I have the following
More informationThe Utility of Atherectomy and the Jetstream Atherectomy System
The Utility of Atherectomy and the Jetstream Atherectomy System William A. Gray, MD Columbia University Medical Center 2014 Boston Scientific Corporation or its affiliates. All rights reserved. IMPORTANT
More informationDisclosures. In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA
In the DCB Era, How Do I Choose To Use a Stent? When to Stent and What Devices to Use in the SFA Disclosures No financial disclosures. Cameron M. Akbari, MD, MBA, FACS Site Director, Vascular Surgery Medstar
More informationDCB From a Pre-Clinical Perspective: The Relevance of Paclitaxel Dose and Coating Integrity
DCB From a Pre-Clinical Perspective: The Relevance of Paclitaxel Dose and Coating Integrity Juan Granada, MD President and CEO Cardiovascular Research Foundation Columbia University Medical Center, New
More informationFabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
Don t Use Risky and Embolizing Drug Coated Balloons Below The Knee! Fabrizio Fanelli, MD, EBIR Director Vascular and Interventional Radiology Department "Careggi " University Hospital Florence - Italy
More informationAccurate Vessel Sizing Drives Clinical Results. IVUS In the Periphery
Accurate Vessel Sizing Drives Clinical Results IVUS In the Periphery Discussion Iida O, et. al. Study Efficacy of Intravascular Ultrasound in Femoropopliteal Stenting for Peripheral Artery Disease With
More informationNeuestes aus der Therapie der pavk. beschichtete Stents + Ballons. Karls-University. Eberhard-Karls. of Tubingen Department of Diagnostic Radiology
Eberhard-Karls Karls-University of Tubingen Department of Diagnostic Radiology Neuestes aus der Therapie der pavk Berlin Dezember 08 beschichtete Stents + Ballons Gunnar Tepe 1 Local Drug Delivery Basic
More informationThe Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience
The Lutonix BTK Clinical Trial Programme: Status Update and Real World Clinical Experience Dierk Scheinert, MD University Hospital Leipzig Leipzig, Germany Disclosure Speaker name: Dierk Scheinert I have
More informationShockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis
Shockwave Intravascular Lithotripsy System treatment of calcified lesions: Intravascular OCT analysis Andrew Holden, MBChB, FRANZCR, EBIR Director of Interventional Radiology Auckland, New Zealand LINC
More informationDrug Elution, Data, and Decisions
Drug Elution, Data, and Decisions What the data tell us about how to integrate drug-eluting technology into our daily practice. BY GARY ANSEL, MD, AND JOHN A. PHILLIPS, MD The use of drug-eluting technology
More informationDISRUPT PAD. (( Data Summary )) DISRUPT PAD Data Summary SPL Rev. B 2016 Shockwave Medical Inc. All rights reserved.
DISRUPT PAD (( Data Summary )) DISRUPT PAD Data Summary SPL 60971 Rev. B 1 Summary of the key findings from the DISRUPT PAD Study 99% of femoropopliteal lesions treated were moderately or severely calcified.
More informationBiology of in-stent restenosis and rational for debulking
LINC 2016 Leipzig January 26-29 2016 Biology of in-stent restenosis and rational for debulking Jos C. van den Berg, MD PhD Ospedale Regionale di Lugano, sede Civico Lugano Switzerland ISR-complexity Osherov
More informationComparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions
Comparison of Angiographic Dissection Patterns Caused by Long vs Short Balloons During Balloon Angioplasty for Chronic Femoropopliteal Occlusions Michinao Tan, MD Tokeidai Memorial Hospital Cardiovascular
More information